UPDATE: The story had incorrectly stated that the test was FDA approved as a companion diagnostic to identify patients with ALK mutations who may respond to the cancer drug Xalkori. We regret the error.

NEW YORK (GenomeWeb) – Thermo Fisher Scientific today said its Oncomine Dx Target Test has received a positive coverage decision from Regence Blue Cross Blue Shield.

As a result, the insurer will cover the test for its members with non-small cell lung cancer in Oregon, Idaho, Utah, and certain counties in Washington.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Rare gene mutations are guiding the search for drugs to manage chronic pain without opioids, according to CNBC.

The new Francis Crick Institute building can get too noisy for some researchers to concentrate, according to the Guardian.

CBS News reports that there are still many vacancies at the White House Office of Science and Technology Policy, but that it's uncertain whether they will be filled.

In Nucleic Acids Research this week: pipeline to analyze and visualize bacterial genomes, database of global set of human genomes, and more.